Enzo Biochem, Inc.
ENZ
$1.09
-$0.02-1.80%
| 01/31/2024 | 10/31/2023 | ||||
|---|---|---|---|---|---|
| Revenue | 9.57% | 2,216.32% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.57% | 2,216.32% | |||
| Cost of Revenue | -0.51% | 204.12% | |||
| Gross Profit | 22.26% | -23.49% | |||
| SG&A Expenses | -27.88% | 142.78% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -19.15% | 5,108.63% | |||
| Operating Income | 60.10% | -6,778.05% | |||
| Income Before Tax | 84.79% | -256.92% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 84.79% | -256.92% | |||
| Earnings from Discontinued Operations | -133.58% | -101.59% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 53.73% | -111.52% | |||
| EBIT | 60.10% | -6,778.05% | |||
| EBITDA | 63.16% | -856.69% | |||
| EPS Basic | 54.02% | -111.25% | |||
| Normalized Basic EPS | 84.87% | -274.07% | |||
| EPS Diluted | 54.02% | -111.26% | |||
| Normalized Diluted EPS | 84.87% | -274.07% | |||
| Average Basic Shares Outstanding | 0.61% | 2.08% | |||
| Average Diluted Shares Outstanding | 0.61% | 2.08% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
